Sort
48,018 grants matching “immunotherapy”
Engineering Tissue Level Targeting of Biologic Drugs via Automated Interfacial Microneedle Pumps
$393,500Alex Abramson · Georgia Institute Of Technology · R35 · FY2024 · GM
Engineering Tissue Level Targeting of Biologic Drugs via Automated Interfacial Microneedle Pumps
$393,500Alex Abramson · Georgia Institute Of Technology · R35 · FY2023 · GM
Engineering Tissue Level Targeting of Biologic Drugs via Automated Interfacial Microneedle Pumps
$393,500Alex Abramson · Georgia Institute Of Technology · R35 · FY2025 · GM
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands
$393,450Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop
$393,450Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2018 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2017 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
$393,450Eric Kirk Lau · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2018 · CA
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands
$393,450Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands
$393,450Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Defining the Complosome in Human Cells, Tissues and Disease States
$393,436John Patterson Atkinson · Washington University · R35 · FY2020 · GM
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$393,420Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2009 · CA
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$393,420Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2010 · CA
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$393,397Cun-Yu Wang · University Of California Los Angeles · R01 · FY2022 · DE
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$393,352Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2020 · CA
Brain Tumor Immunotherapy
$393,294Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Rare Central Nervous System Cancers Initiative
$393,294Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Inducing NK cells to remember and fight cancer
$393,292Jeffrey S Miller · University Of Minnesota · R01 · FY2015 · HL
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
$393,267Sukyung Woo · State University Of New York At Buffalo · R01 · FY2025 · CA